HSF2BP Interacts with a Conserved Domain of BRCA2 and Is Required for Mouse Spermatogenesis.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
25 06 2019
Historique:
received: 16 07 2018
revised: 01 05 2019
accepted: 23 05 2019
entrez: 27 6 2019
pubmed: 27 6 2019
medline: 31 7 2020
Statut: ppublish

Résumé

The tumor suppressor BRCA2 is essential for homologous recombination (HR), replication fork stability, and DNA interstrand crosslink repair in vertebrates. We identify HSF2BP, a protein previously described as testis specific and not characterized functionally, as an interactor of BRCA2 in mouse embryonic stem cells, where the 2 proteins form a constitutive complex. HSF2BP is transcribed in all cultured human cancer cell lines tested and elevated in some tumor samples. Inactivation of the mouse Hsf2bp gene results in male infertility due to a severe HR defect during spermatogenesis. The BRCA2-HSF2BP interaction is highly evolutionarily conserved and maps to armadillo repeats in HSF2BP and a 68-amino acid region between the BRC repeats and the DNA binding domain of human BRCA2 (Gly2270-Thr2337) encoded by exons 12 and 13. This region of BRCA2 does not harbor known cancer-associated missense mutations and may be involved in the reproductive rather than the tumor-suppressing function of BRCA2.

Identifiants

pubmed: 31242413
pii: S2211-1247(19)30735-1
doi: 10.1016/j.celrep.2019.05.096
pii:
doi:

Substances chimiques

BRCA2 Protein 0
BRCA2 protein, human 0
BRCA2 protein, mouse 0
Carrier Proteins 0
HSF2BP protein, mouse 0
Heat-Shock Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3790-3798.e7

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Inger Brandsma (I)

Department of Molecular Genetics, Oncode Institute, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands.

Koichi Sato (K)

Oncode Institute, Hubrecht Institute-KNAW and University Medical Center Utrecht, 3584 CT Utrecht, the Netherlands.

Sari E van Rossum-Fikkert (SE)

Department of Molecular Genetics, Oncode Institute, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands; Department of Radiation Oncology, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands.

Nicole van Vliet (N)

Department of Molecular Genetics, Oncode Institute, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands.

Esther Sleddens (E)

Department of Developmental Biology, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands.

Marcel Reuter (M)

Department of Molecular Genetics, Oncode Institute, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands.

Hanny Odijk (H)

Department of Molecular Genetics, Oncode Institute, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands.

Nathalie van den Tempel (N)

Department of Molecular Genetics, Oncode Institute, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands.

Dick H W Dekkers (DHW)

Proteomics Center, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands.

Karel Bezstarosti (K)

Proteomics Center, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands.

Jeroen A A Demmers (JAA)

Proteomics Center, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands.

Alex Maas (A)

Department of Cell Biology, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands.

Joyce Lebbink (J)

Department of Molecular Genetics, Oncode Institute, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands; Department of Radiation Oncology, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands.

Claire Wyman (C)

Department of Molecular Genetics, Oncode Institute, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands; Department of Radiation Oncology, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands.

Jeroen Essers (J)

Department of Molecular Genetics, Oncode Institute, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands; Department of Radiation Oncology, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands; Department of Vascular Surgery, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands.

Dik C van Gent (DC)

Department of Molecular Genetics, Oncode Institute, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands.

Willy M Baarends (WM)

Department of Developmental Biology, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands.

Puck Knipscheer (P)

Oncode Institute, Hubrecht Institute-KNAW and University Medical Center Utrecht, 3584 CT Utrecht, the Netherlands. Electronic address: p.knipscheer@hubrecht.eu.

Roland Kanaar (R)

Department of Molecular Genetics, Oncode Institute, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands. Electronic address: r.kanaar@erasmusmc.nl.

Alex N Zelensky (AN)

Department of Molecular Genetics, Oncode Institute, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands. Electronic address: a.zelensky@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH